Podcast: What Should the FDA Do When Drug Tests Are Tainted?
In an investigation published yesterday, Rob Garver and Charles Seife shared the story of how the Food and Drug Administration found a lab in Houston, Texas, that had provided the agency with drug tests tainted by "egregious" research misconduct. While the FDA's counterpart in Europe took seven of the improperly tested drugs off the market, the FDA did not follow suit.
Garver and Seife joined the podcast to discuss how the FDA typically handles situations like this, how the agency found out the tests were not conducted improperly, why the European Medicines Agency pulled the drugs, which drugs were involved, and why the FDA has not been forthcoming with more information.
"We certainly believe that the FDA ought to be more transparent, but it's not just us," said Garver. "Dr. David Kessler, the former head of the FDA, is on the record in the story concerned that the FDA hasn't been sufficiently transparent about this. He says that you can't just ask the public to trust you."
Seife added, "I think they (consumers) have to be worried about the process rather than any individual drug. The FDA is the watchdog — it is the agency that is supposed to keep us safe. And when it says that it can't tell us why these drugs are put on the market, despite the fact that we know that their experimental basis for the safety and efficacy of these drugs is undermined, [that] makes us question whether the FDA is hiding something."
Our Hottest Stories
- Meet the Online Tracking Device That is Virtually Impossible to Block
- California Halts Injection of Fracking Waste, Warning it May Be Contaminating Aquifers
- Campus Sexual Assault: What Are Colleges Doing Wrong?
- What We Learned Investigating Unpaid Internships
- Who Advised Cuomo on Mortgage Industry Investigation? A Mortgage Lobbyist
- Are Patient Privacy Laws Being Misused to Protect Medical Centers?
- Thank You for Your Service: How One Company Sues Soldiers Worldwide
- New York State of Fracking: A ProPublica Explainer
- Error: You Have No Payments from Pharma
- Even After Open Enrollment, Activity Remains Unexpectedly High on Federal Health Insurance Exchange